Recombinant Cynomolgus TIM-1/KIM-1/HAVCR Fc Chimera, CF

Recombinant Cynomolgus Monkey TIM‑1/KIM‑1/HAVCR Fc Chimera (Catalog # 9676-TM) inhibits anti-CD3-induced proliferation of PHA-activated human T cells. The ED50 for this effect is 0.4-2.4 μg/mL.

• Reactivity: Pm-Cm
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Cynomolgus TIM-1/KIM-1/HAVCR Fc Chimera, CF Summary

• Details of Functionality: Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated human T cells. The ED₅₀ for this effect is 0.4-2.4 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived cynomolgus monkey TIM-1/KIM-1/HAVCR protein
  

  Cynomolgus Monkey TIM-1/KIM-1/HAVCR (Val18-Thr253) Accession # BAJ61042	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: BAJ61042
• N-terminal Sequence: Val18, Asp20, & Val22
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 52 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 91-107 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Cynomolgus TIM-1/KIM-1/HAVCR Fc Chimera, CF

• CD365
• HAVCR1
• HAVCR-1
• HAVCRT cell immunoglobin domain and mucin domain protein 1
• hepatitis A virus cellular receptor 1
• Kidney injury molecule 1
• KIM1
• KIM-1
• T-cell immunoglobulin and mucin domain-containing protein 1
• TIM1
• TIM-1
• TIM-1TIM
• TIM1TIMD-1
• TIMD1T-cell membrane protein 1

Background

T cell immunoglobulin and mucin domain 1 (TIM-1), also known as KIM-1 and HAVcr1, is a member of the TIM family which is involved in the regulation of innate and adaptive immune responses (1). TIM-1 is a type I transmembrane protein that contains an N-terminal immunoglobulin-like domain, a mucin domain with O- and N-linked carbohydrates, a transmembrane segment, and a cytoplasmic signaling domain (2). Multiple TIM-1 variants can be produced due to polymorphisms or alternative splicing resulting in deletions in the mucin domain. TIM-1 is also known to circulate as a soluble form. Constitutive cleavage by an undefined MMP (possibly ADAM33) releases an 85-90 kDa soluble molecule (3). TIM-1 is expressed on splenic B cells, IL-10⁺ regulatory B cells, CD4⁺ T cells, mast cells, invariant NKT (iNKT) cells, dendritic cells, kidney epithelium and a broad range of mucosal epithelium (1, 4-6). It is up-regulated on activated Th2 cells, after dendritic cell maturation, and on kidney tubular epithelial cells after injury (7-10). Within the extracellular domain, Cynomolgus monkey TIM-1 shares 69% and 44% amino acid sequence identity with human and mouse TIM-1, respectively. The only two reported ligands for TIM-1 are TIM-4 and the hepatitis A virus (2, 11). However, others are believed to exist, and based on the ligand for TIM-3, one may well be an S-type lectin (12). TIM-1 ligation induces T cell proliferation and promotes cytokine production (12).

1. Du, P. et al. (2016) J. Immunol. Res. 2016:8605134.
2. Feigelstock, D. et al. (1998) J. Virol. 72:6621.
3. Bailly, V. et al. (2002) J. Biol. Chem. 277:39739.
4. Ding, Q. et al. (2011) J. Clin. Invest. 121:3645.
5. Ma, J. et al. (2011) Biochem. Biophys. Res. Commun. 406:223.
6. de Souza, A.J. et al. (2005) Proc. Natl. Acad. Sci. USA 102:17113.
7. Kuehn, E.W. et al. (2002) Am. J. Physiol. Renal Physiol. 283:F1326.
8. Umetsu, S.E. et al. (2005) Nat. Immunol. 6:447.
9. Xiao, S. et al. (2011) Eur. J. Immunol. 41:1539.
10. Ichimura, T. et al. (1998) J. Biol. Chem. 273:4135.
11. Zhu, C. et al. (2005) Nat. Immunol. 6:1245.
12. Meyers, J.H. et al. (2005) Nat. Immunol. 6:455.

Bioinformatics

• Uniprot:
  • BAJ61042()